Celyad reports promising early results at first dose level of the solid arm of the THINK trial – Nasdaq
|
Celyad reports promising early results at first dose level of the solid arm of the THINK trial
Nasdaq MONT-SAINT-GUIBERT, Belgium, June 19, 2017 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered CAR–T cell therapies, today announces promising early … |
